---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-075416"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:20:30.845411+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phoenix Biotech receives Nasdaq deficiency notice for minimum public holders rule

## Summary
- Received Nasdaq notice on Sep 7, 2023, for non-compliance with Minimum Public Holders Rule (400 public holders required for Nasdaq Global Market).
- Has 45 calendar days to submit a plan to regain compliance; intends to submit within timeframe.
- If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, can appeal to Hearings Panel.
- Also pursuing a business combination with CERo Therapeutics (previously filed Form S-4).
- Notice is not an imminent delisting; no current effect on listing or trading of PBAX securities.

## SEC filing metadata
- accession: 0001213900-23-075416
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/0001213900-23-075416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/ea184886-8k425_phoenix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-075416
- JSON: https://secwatch.observer/filing/0001213900-23-075416.json
- Plain text: https://secwatch.observer/filing/0001213900-23-075416.txt

## Key facts
- Listing & Compliance Notices
  CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5450(a)(2)
  source text: September 7, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(a)(2), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s se
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390023075416/0001213900-23-075416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.